Arax Capital Partners
VC Fund
Vienna, Austria
ARAX Capital Partners is an Austrian bio-tech and high-tech early stage investor with an exclusive focus on Austrian ventures. Companies need to be young, innovative (if possible with patentable technology) and must have already secured pre-seed funding to qualify for an investment
- Total investments:
- 6
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Arax Capital Partners invests in
Stages Arax Capital Partners invests in
Countries Arax Capital Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.1M–$1.1M
Investment Focus
Industry
- Biotechnology 3 (50%)
- Health Care 2 (33%)
- SaaS 1 (17%)
- Medical 1 (17%)
- CleanTech 1 (17%)
Stage
- Seed 3 (50%)
- Funding Round 2 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Christian Tiringer
Partner and Founder
|
Partner and Founder | Total investments: 0 | Find email | |
|
Daniel Cesky
Partner
|
Partner | Total investments: 0 | Find email | |
|
Lena Skaper
Office Management
|
Office Management | Total investments: 0 | Find email | |
|
Michael Stranz
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
|
Rumman Syed
Managing Director - Smart Capital GmbH
|
Managing Director - Smart Capital GmbH | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Greenpass
|
Greenpass is an all-in-one SaaS for climate-resilient urban planning & architecture platform that enables livable cities. | Seed / Sep 24, 2024 | |
|
Calyxha Biotechnologies
|
Calyxha is developing novel therapies targeting tissue degeneration that is the fundamental underlying cause of major human diseases. | $1.1M / Seed / Feb 28, 2020 | |
|
Calyxha Biotechnologies
|
Calyxha is developing novel therapies targeting tissue degeneration that is the fundamental underlying cause of major human diseases. | $1.1M / Seed / Feb 28, 2020 | |
AFFiRiS
|
AFFiRiS AG, a Vienna, Austria-based developer of tailor-made peptide vaccines for Alzheimer's disease, Atherosclerosis, Parkinson's disease, hypertension and several other conditions. | $10M / Jun 28, 2016 | |
Panoptes Pharma
|
Panoptes is a privately held biotech company focused on developing small molecule based therapies for the treatment of severe eye diseases with high unmet medical need. Panoptes is located in the city center of Vienna, Austria.The development of Panoptes´ clinical candidate PP-001 focuses on a new treatment for autoimmune uveitis, a disease whichis one of the major causes of blindness. As a second indication, adenoviral conjunctivitis will be pursued, a disease for which to date, no treatment is available. Due to its unique mode of action, PP-001 has therapeutic potential for additional inflammatory and viral indications.Panoptes has an experienced team of development experts with a proven track record of developing and commercializing innovative products. The team is developing a focused portfolio of high-performance small molecule products, with its lead clinical candidate PP-001 in preclinical development. | Seed / Nov 02, 2015 | |
Biocrates Life Sciences
|
Biocrates is a developer of a metabolomics platform designed to support the discovery and validation of biomarkers for complex diseases. The company's metabolomics platform comprises an automated sample preparation workflow integrated with sensitive mass-spectrometric methods and software that controls sample management, data collection, andanalysis to identify hundreds of metabolites, enabling physicians to acquire comprehensive metabolic information quickly and reliably. | $1.6M / Mar 25, 2010 |
Co-Investors
aws Gründungsfonds
2 deals together
Bloom Family Office
2 deals together
Kinled Holding
2 deals together
LifeLink Ventures
2 deals together
MIG Capital
2 deals together
4SC
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Arax Capital Partners invest in?
Arax Capital Partners invests primarily in Biotechnology, Health Care and SaaS startups, most often at Seed and Funding Round stage. Most of the 6 investments tracked by Shizune back companies in Austria. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Arax Capital Partners's check size?
Arax Capital Partners typically joins rounds of $1.1M–$1.1M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Arax Capital Partners participates in.
How do I contact Arax Capital Partners?
Public channels for Arax Capital Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Arax Capital Partners?
The team at Arax Capital Partners includes Christian Tiringer (Partner and Founder), Daniel Cesky (Partner) and Lena Skaper (Office Management). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
